Literature DB >> 29517518

PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics.

Maria Alvarellos1, Chantal Guillemette2, Russ B Altman3,4, Teri E Klein1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29517518      PMCID： PMC5910198          DOI： 10.1097/FPC.0000000000000331

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  74 in total

1.  Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency.

Authors:  Wan Beom Park; Pyoeng Gyun Choe; Kyoung-Ho Song; Jae Hyun Jeon; Sang Won Park; Hong Bin Kim; Nam Joong Kim; Myoung-Don Oh; Kang Won Choe
Journal:  Clin Infect Dis       Date:  2010-07-01       Impact factor: 9.079

2.  Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial.

Authors:  Cynthia Firnhaber; Laura M Smeaton; Beatriz Grinsztejn; Umesh Lalloo; Sharla Faesen; Wadzanai Samaneka; Rosa Infante; Aadia Rana; Nagalingeswaran Kumarasamy; James Hakim; Thomas B Campbell
Journal:  HIV Clin Trials       Date:  2015-05-15

3.  PharmGKB summary: voriconazole pathway, pharmacokinetics.

Authors:  Julia M Barbarino; Aniwaa Owusu Obeng; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

4.  Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype.

Authors:  Tim O Lankisch; Ulrike Moebius; Michael Wehmeier; Georg Behrens; Michael P Manns; Reinhold E Schmidt; Christian P Strassburg
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

5.  Complicated atazanavir-associated cholelithiasis: a report of 14 cases.

Authors:  Soloniaina Rakotondravelo; Yves Poinsignon; Françoise Borsa-Lebas; Arnaud de la Blanchardière; Christophe Michau; Hélène Jantzem; Nathalie Massy; Elisabeth Polard; Fanny Giroux; Hélène Kerspern; Ahmed Meskar; Guy Hue; Olivier Tribut; Cédric Arvieux; Pierre Tattevin
Journal:  Clin Infect Dis       Date:  2012-07-19       Impact factor: 9.079

6.  Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

Authors:  Qing Ma; Daniel Brazeau; Barry S Zingman; Richard C Reichman; Margaret A Fischl; Barbara M Gripshover; Charles S Venuto; Judianne C Slish; Robin DiFrancesco; Alan Forrest; Gene D Morse
Journal:  Pharmacogenomics       Date:  2007-03       Impact factor: 2.533

Review 7.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Authors:  R S Gammal; M H Court; C E Haidar; O F Iwuchukwu; A H Gaur; M Alvarellos; C Guillemette; J L Lennox; M Whirl-Carrillo; S S Brummel; M J Ratain; T E Klein; B R Schackman; K E Caudle; D W Haas
Journal:  Clin Pharmacol Ther       Date:  2015-11-09       Impact factor: 6.875

8.  Pharmacokinetics of an increased atazanavir dose with and without tenofovir during the third trimester of pregnancy.

Authors:  Regis Kreitchmann; Brookie M Best; Jiajia Wang; Alice Stek; Edmund Caparelli; D Heather Watts; Elizabeth Smith; David E Shapiro; Steve Rossi; Sandra K Burchett; Elizabeth Hawkins; Mark Byroads; Tim R Cressey; Mark Mirochnick
Journal:  J Acquir Immune Defic Syndr       Date:  2013-05-01       Impact factor: 3.731

9.  Evaluating the in vitro inhibition of UGT1A1, OATP1B1, OATP1B3, MRP2, and BSEP in predicting drug-induced hyperbilirubinemia.

Authors:  Jae H Chang; Emile Plise; Jonathan Cheong; Quynh Ho; Molly Lin
Journal:  Mol Pharm       Date:  2013-06-21       Impact factor: 4.939

10.  Cholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral Therapy.

Authors:  Kuan-Yin Lin; Sih-Han Liao; Wen-Chun Liu; Aristine Cheng; Shu-Wen Lin; Sui-Yuan Chang; Mao-Song Tsai; Ching-Hua Kuo; Mon-Ro Wu; Hsiu-Po Wang; Chien-Ching Hung; Shan-Chwen Chang
Journal:  PLoS One       Date:  2015-09-11       Impact factor: 3.240
View more
  1 in total

1.  Methadone serum concentrations and influencing factors: A naturalistic observational study.

Authors:  Fatemeh Chalabianloo; Andreas A Westin; Eirik Skogvoll; Jørgen G Bramness; Olav Spigset
Journal:  Psychopharmacology (Berl)       Date:  2019-05-28       Impact factor: 4.530
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.